Zhao Jun, Yu Hai-Yang, Zhao Yu, Li Feng-Hua, Zhou Wei, Xia Bin-Bin, He Zhi-Yuan, Chen Jason, Jiang Guo-Tuo, Wang Ming-Li
a Department of Microbiology , Anhui Medical University , Hefei , Anhui , P.R. China.
b Anhui JiuChuan Biotech Co., Ltd , Wuhu , Anhui , P.R. China.
Prep Biochem Biotechnol. 2019;49(2):192-201. doi: 10.1080/10826068.2019.1566150. Epub 2019 Feb 8.
In this paper, we report a soluble expression based on Escherichia coli and two-step purification of a novel thioredoxin-tagged chicken interferon-α fusion protein (Trx-rChIFN-α) by using pET32a(+) expression system. The mature ChIFN-α gene was amplified by Reverse transcriptase-polymerase chain reaction (RT-PCR) and subcloned into pET-32a (+) vector prior to transformation into Rosetta (DE3) competent cells. After IPTG induction, the recombinant fusion protein was expressed efficiently in the soluble fraction. The protein purification was performed by nickel affinity chromatography and DEAE anion exchange chromatography. The purified product has a purity of 95% with a yield of 47.3 mg/L of culture. The specific activity of the fusion protein reaches to 2.0 × 10 IU/mg as determined in the CEF/VSV titration system. After excision of the Trx tag by enterokinase, the remaining solo protein was confirmed as rChIFN-α protein by SDS-PAGE, N-terminal sequencing and mass spectrometry. The effects of this Trx-rChIFN-α fusion protein against H9N2 influenza virus infection were also evaluated in ovo. The results showed that the Trx-rChIFN-α protein could significantly reduce the hemagglutination titer of H9N2 virus, and the H9N2 viruses HA gene copy numbers. These findings will enable us to produce large amount and bio-active rChIFN-α protein for future applications.
在本文中,我们报道了基于大肠杆菌的可溶性表达以及使用pET32a(+)表达系统对新型硫氧还蛋白标记的鸡α干扰素融合蛋白(Trx-rChIFN-α)进行两步纯化的方法。通过逆转录聚合酶链反应(RT-PCR)扩增成熟的ChIFN-α基因,并在转化到Rosetta (DE3)感受态细胞之前将其亚克隆到pET-32a(+)载体中。IPTG诱导后,重组融合蛋白在可溶性部分高效表达。通过镍亲和层析和DEAE阴离子交换层析进行蛋白质纯化。纯化产物的纯度为95%,培养物产量为47.3 mg/L。在CEF/VSV滴定系统中测定,融合蛋白的比活性达到2.0×10 IU/mg。用肠激酶切除Trx标签后,通过SDS-PAGE、N端测序和质谱确认剩余的单一蛋白为rChIFN-α蛋白。还在鸡胚内评估了这种Trx-rChIFN-α融合蛋白对H9N2流感病毒感染的作用。结果表明,Trx-rChIFN-α蛋白可显著降低H9N2病毒的血凝滴度以及H9N2病毒HA基因的拷贝数。这些发现将使我们能够大量生产具有生物活性的rChIFN-α蛋白以供未来应用。